Cargando…
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only...
Autores principales: | Jung, Chi Young, Antonia, Scott J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771744/ https://www.ncbi.nlm.nih.gov/pubmed/29332322 http://dx.doi.org/10.4046/trd.2017.0120 |
Ejemplares similares
-
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023) -
Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor
por: Seo, Jeong-Sun, et al.
Publicado: (2018) -
Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer
por: Jiang, Li, et al.
Publicado: (2022) -
Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non‐small cell lung cancer
por: Khatir, Wassila, et al.
Publicado: (2022) -
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
por: Qiu, Zhenbin, et al.
Publicado: (2019)